Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)

H. Hammer, N. Kamber, M. Pistor, L. Diem, C. Friedli, A. Chan, R. Hoepner, A. Salmen

Research output: Contribution to journalLetterpeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)'. Together they form a unique fingerprint.

Medicine & Life Sciences